For BioNTech SE [BNTX], Analyst sees a rise to $294. What next?

Related

BioNTech SE [NASDAQ: BNTX] closed the trading session at $240.61 on 12/29/21. The day’s price range saw the stock hit a low of $231.73, while the highest price level was $244.30. The company report on December 27, 2021 that BioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference.

MAINZ, Germany, December 27, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 9:45 am ET.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


A live webcast of the presentation will be available via the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://biontech.de/. The replay of the webcast will be archived on the Company’s website for 30 days following the conference.

The stocks have a year to date performance of 195.15 percent and weekly performance of -11.36 percent. The stock has been moved at 7.47 percent over the last six months. The stock has performed -33.63 percent around the most recent 30 days and changed -13.27 percent over the most recent 3-months.

If compared to the average trading volume of 3.32M shares, BNTX reached to a volume of 2708281 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about BioNTech SE [BNTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNTX shares is $322.18 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNTX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for BioNTech SE shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on December 16, 2021. The new note on the price target was released on November 10, 2021, representing the official price target for BioNTech SE stock. Previously, the target price had yet another raise to $250, while Deutsche Bank analysts kept a Hold rating on BNTX stock.

The Average True Range (ATR) for BioNTech SE is set at 21.74, with the Price to Sales ratio for BNTX stock in the period of the last 12 months amounting to 3.80. The Price to Book ratio for the last quarter was 5.96, with the Price to Cash per share for the same quarter was set at 10.99. Price to Free Cash Flow for BNTX in the course of the last twelve months was 42.79 with Quick ratio for the last quarter at 2.70.

BNTX stock trade performance evaluation

BioNTech SE [BNTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.36. With this latest performance, BNTX shares dropped by -33.63% in over the last four-week period, additionally plugging by 7.47% over the last 6 months – not to mention a rise of 172.55% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNTX stock in for the last two-week period is set at 37.36, with the RSI for the last a single of trading hit 30.08, and the three-weeks RSI is set at 41.18 for BioNTech SE [BNTX]. The present Moving Average for the last 50 days of trading for this stock 280.72, while it was recorded at 250.37 for the last single week of trading, and 251.78 for the last 200 days.

BioNTech SE [BNTX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and BioNTech SE [BNTX] shares currently have an operating margin of -55.27 and a Gross Margin at +87.76. BioNTech SE’s Net Margin is presently recorded at +3.15.

Return on Total Capital for BNTX is now -23.29, given the latest momentum, and Return on Invested Capital for the company is 1.34. Return on Equity for this stock inclined to 1.55, with Return on Assets sitting at 0.93. When it comes to the capital structure of this company, BioNTech SE [BNTX] has a Total Debt to Total Equity ratio set at 17.51. Additionally, BNTX Total Debt to Total Capital is recorded at 14.90, with Total Debt to Total Assets ending up at 10.36. Long-Term Debt to Equity for the company is recorded at 16.84, with the Long-Term Debt to Total Capital now at 14.33.

Reflecting on the efficiency of the workforce at the company, BioNTech SE [BNTX] managed to generate an average of $8,926 per employee. Receivables Turnover for the company is 4.86 with a Total Asset Turnover recorded at a value of 0.29.BioNTech SE’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.80.

>> 7 Top Picks for the Post-Pandemic Economy <<

BioNTech SE [BNTX]: Insider Ownership positions

There are presently around $8,845 million, or 17.20% of BNTX stock, in the hands of institutional investors. The top three institutional holders of BNTX stocks are: BAILLIE GIFFORD & CO with ownership of 6,345,313, which is approximately -1.313% of the company’s market cap and around 1.18% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 4,283,358 shares of the stock with an approximate value of $1.03 billion in BNTX stocks shares; and JENNISON ASSOCIATES LLC, currently with $983.36 million in BNTX stock with ownership of nearly 1473.688% of the company’s market capitalization.

Positions in BioNTech SE stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 178 institutional holders increased their position in BioNTech SE [NASDAQ:BNTX] by around 8,152,889 shares. Additionally, 133 investors decreased positions by around 6,372,834 shares, while 51 investors held positions by with 22,114,750 shares. The mentioned changes placed institutional holdings at 36,640,473 shares, according to the latest SEC report filing. BNTX stock had 87 new institutional investments in for a total of 2,125,605 shares, while 34 institutional investors sold positions of 1,179,803 shares during the same period.